ATG5 and triple-A syndrome: Our study did not investigate the reason for this discrepancy, but it may be due to differences in the mouse model of AAA (angiotensin II‐treated Atg5‐deficient mice with TGF‐β inhibition vs. angiotensin II‐infused Atg7‐deficient mice without TGF‐β inhibition).